Amgen Inc.

William Gleason Richards

Hsieng Sen Lu

Frederick W Jacobsen

Hua Zhu Ke

Chaoyang Li

Wenyan Shen

Ji Li

Taruna Arora

David R Martin

Joanne Louise Viney

Gordon Ng

John Peter Geibel

Monica Florio

Christopher J R Paszty

Steven Charles Hebert

The present invention provides antibodies and immunologically functional fragments thereof that specifically bind DKK1 polypeptides. Methods for preparing such antibodies or fragments thereof as well as physiologically acceptable compositions containing the antibodies or fragments are also provided. Use of the antibodies and fragments to treat various diseases are also disclosed.

DKK1 antibodies and methods of use

The invention relates to bispecific anti-sclerostin/anti-DKK1 binding agents and combinations of anti-sclerostin and anti-DKK1 binding agents, and related methods of treatment.

Bispecific binding agents

This invention relates generally to the field of medicine and, more specifically, to methods for treating epithelial injury, in particular, due to ischemia, hypoxia, trauma, chemolytics or radiation exposure.

Calcimimetic compound for use in the treatment of epithelial injury

The present invention provides antibodies and immunologically functional fragments thereof that specifically bind Dkk-1 polypeptides. The subject antibodies and fragments bind with high affinity to a conformational epitope located in the carboxy region of the Dkk-1 protein. Methods for preparing such antibodies or fragments thereof as well as physiologically acceptable compositions containing the antibodies or fragments are also provided. Use of the antibodies and fragments to treat various diseases including bone disorders, inflammatory diseases, neurological diseases, ocular diseases, renal diseases, pulmonary diseases and skin diseases are also disclosed.

Treatment methods using Dkk-1 antibodies

Antibodies to Dkk-1

Growing community of inventors

Thousand Oaks, CA, United States of America

William Gleason Richards